BRIEF-Intercept Pharma says patients treated with Ocaliva UDCA had significantly improved estimated liver transplant-free survival
April 14, 2016 at 07:47 AM EDT
* Of 216 randomized patients in poise trial, 93% continued receiving ursodeoxycholic acid (UDCA) upon initiating ocaliva or placebo